Imelda Ontoria Oviedo

Title: Imelda Ontoria Oviedo: Innovator in Cardiotoxicity Prediction

Introduction

Imelda Ontoria Oviedo is a prominent inventor based in Valencia, Spain. She has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. Her innovative approach has the potential to improve patient outcomes and enhance treatment safety.

Latest Patents

Imelda Ontoria Oviedo holds a patent for her invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity based on the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA 192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also proposes a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.

Career Highlights

Throughout her career, Imelda has worked with notable institutions, including the Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana and Maastricht University. Her work has focused on advancing the understanding of cardiotoxicity in cancer treatments, contributing to both academic research and practical applications in healthcare.

Collaborations

Imelda has collaborated with esteemed colleagues such as David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have enriched her research and expanded the impact of her innovations in the medical field.

Conclusion

Imelda Ontoria Oviedo is a trailblazer in the realm of cardiotoxicity prediction, with her patented invention poised to make a significant difference in cancer treatment. Her dedication to improving patient care through innovative research exemplifies the vital role of inventors in advancing medical science.